Advanced Non-small Cell Lung Cancer (NSCLC)
Oncology·MeSH: Neoplasm, Residual
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| Alimta® | ELI LILLY & Co (LLY) |
Phase 2(1)
Frequently asked questions
How many drugs are in development for Advanced Non-small Cell Lung Cancer (NSCLC)?
BioSniper tracks 2 drugs in development for Advanced Non-small Cell Lung Cancer (NSCLC) across 2 companies.
How many clinical trials target Advanced Non-small Cell Lung Cancer (NSCLC)?
There are 1 clinical trial targeting Advanced Non-small Cell Lung Cancer (NSCLC) tracked by BioSniper.
Analyze ELI LILLY & Co's Advanced Non-small Cell Lung Cancer (NSCLC) pipeline with AI
Full trial data, competitive analysis, and AI-powered pipeline tracking.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company